U.S. Markets open in 2 hrs 12 mins

Initiating Free Research Reports on Pieris Pharma and Three Other Biotech Equities

Stock Research Monitor: PACB, PRTK, and PDLI

LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on PIRS sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com assesses Pacific Biosciences of California Inc. (NASDAQ: PACB), Paratek Pharmaceuticals Inc. (NASDAQ: PRTK), PDL BioPharma Inc. (NASDAQ: PDLI), and Pieris Pharmaceuticals Inc. (NASDAQ: PIRS). These stocks belong to the Biotech space, which produces medicine that have a biological basis. Biotechnology companies use live organisms or their products, such as bacteria or enzymes, to manufacture their medicines. All you have to do is sign up today for this free limited time offer by clicking the link below:

www.wallstequities.com/registration

Pacific Biosciences of California

Menlo Park, California headquartered Pacific Biosciences of California Inc.'s stock finished Tuesday's session 2.72% lower at $3.58 with a total trading volume of 400,053 shares. The Company's shares have advanced 5.29% in the past month, 37.69% over the previous three months, and 3.17% over the past year. The stock is trading above its 50-day and 200-day moving averages by 16.03% and 18.64%, respectively. Furthermore, shares of the Company, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have a Relative Strength Index (RSI) of 53.90.

On July 10th, 2018, Pacific Biosciences of California announced that a multi-institutional consortium of maize researchers is using the Sequel® System to create a 26-line pangenome reference collection. Led by faculty investigator R. Kelly Dawe, Distinguished Research Professor at the University of Georgia, the $2.8-million National Science Foundation-funded Plant Genome Research Project will create comprehensive, high-quality assemblies of 25 inbreds known as the NAM founder lines, the most extensively researched maize lines that represent a broad cross section of modern maize diversity, as well as an additional line containing abnormal chromosome 10. Get the full research report on PACB for free by clicking below at:

www.wallstequities.com/registration/?symbol=PACB

Paratek Pharmaceuticals

Shares in Boston, Massachusetts headquartered Paratek Pharmaceuticals Inc. ended at $10.45, down slightly by 0.48% from the last trading session. The stock recorded a trading volume of 367,971 shares. The Company's shares are trading 2.58% below their 50-day moving average. Moreover, shares of Paratek Pharma, which focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the US, have an RSI of 46.41.

On June 20th, 2018, Paratek Pharmaceuticals announced that a meeting of the Antimicrobial Drugs Advisory Committee of the US FDA has been scheduled for August 08th, 2018, to review the Company's New Drug Applications for once-daily, oral, and intravenous omadacycline. Omadacycline is under review for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Gain free access to the research report on PRTK at:

www.wallstequities.com/registration/?symbol=PRTK

PDL BioPharma

Incline Village, Nevada headquartered PDL BioPharma Inc.'s stock ended yesterday's session flat at $2.56 with a total trading volume of 792,883 shares. The Company's shares have advanced 1.59% in the past month and 7.11% over the past year. The stock is trading 3.33% below its 50-day moving average. Additionally, shares of PDL BioPharma, which acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the US, Europe, and internationally, have an RSI of 53.36.

On June 22nd, 2018, PDL BioPharma announced that retired Eli Lilly and Co.'s executive, Elizabeth G. O'Farrell, has been named to the former's Board of Directors, effective that day, increasing its number of directors to nine. Ms. O'Farrell retired from a 24-year career with Eli Lilly, most recently serving as Chief Procurement Officer from 2012 to 2017. Signing up today on Wall St. Equities will give you access to the latest report on PDLI at:

www.wallstequities.com/registration/?symbol=PDLI

Pieris Pharmaceuticals

On Tuesday, shares in Boston, Massachusetts headquartered Pieris Pharmaceuticals Inc. recorded a trading volume of 379,244 shares. The stock finished 3.48% lower at $5.55. The Company's shares have advanced 7.35% in the last month. The stock is trading below its 50-day moving average by 0.70%. Furthermore, shares of Pieris Pharma, which discovers and develops anticalin-based drugs in the US, have an RSI of 53.07. Register now for today's free coverage on PIRS at:

www.wallstequities.com/registration/?symbol=PIRS

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities